CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast...
Phase 1
Houston, Texas, United States and 3 other locations
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...
Phase 1, Phase 2
Houston, Texas, United States and 49 other locations
dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative b ...
Phase 1
Houston, Texas, United States and 1 other location
oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoin ...
Phase 2
Houston, Texas, United States and 23 other locations
This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...
Phase 2
Houston, Texas, United States and 3 other locations
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Houston, Texas, United States and 216 other locations
avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...
Phase 2
Houston, Texas, United States and 11 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Houston, Texas, United States and 161 other locations
To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast...
Phase 2
Houston, Texas, United States
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Houston, Texas, United States and 199 other locations
Clinical trials
Research sites
Resources
Legal